Söndag 22 December | 12:18:38 Europe / Stockholm

Prenumeration

2024-12-06 11:18:00
  • High interest amid progression of the projects
  • The rights issue in Q4 added MSEK 14.1
  • We keep our fair value of SEK 7.60 per share

Bioextrax has received numerous inquiries from research institutes and companies since the summer. At the same time, the company reports steady progress from its leading projects. In Q4, Bioextrax raised MSEK 14.1 to prolong its financial runway until 2026.

Read the full report here.